Skip to main content
Caplight Logo









Attivare Therapeutics

Attivare Therapeutics

Private
Natick, MassachusettsHealthcare & Life Scienceshttps://attivaretx.com/

Last Round

Grant

Dec 15, 2025

Total Funding Raised

$12.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Attivare Therapeutics is a biotechnology company that develops personalized immunotherapies and vaccine platforms using a proprietary biomaterial scaffold technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

biotechnologyimmunotherapybiomaterial scaffolddrug deliveryoncologybiotechdrug discoveryprecision medicinein vivoimmune reprogrammingmesoporous silicaAI drug discoveryinfectious diseasetherapeutic platformbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attivare Therapeutics Comparables

Compare Attivare Therapeutics with similar companies based on industry and business-model similarity.

Attivare Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SURGE Therapeutics
76%
ImmunoVec
71%
Flashpoint Therapeutics
70%

Attivare Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 15, 2025
SeedDec 2, 2021

Key People

Founding team and executive leadership

David Sherris

President and CEO

Executive Team

Attivare Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 15, 2025

    Received $7M from the Bill & Melinda Gates Foundation.

  • Dec 2, 2021

    $6M round led by FundRx.

Attivare Therapeutics Filings

Explore SEC and related filing metadata, where available.

Attivare Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Attivare Therapeutics's valuation, stock price, and market status.

Is Attivare Therapeutics a public or private company?

Attivare Therapeutics is a private company.

What is the current stock price of Attivare Therapeutics?

Attivare Therapeutics is a private company with no public stock price. Caplight tracks Attivare Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Attivare Therapeutics worth (valuation)?

Valuation information for Attivare Therapeutics is not publicly available.

Can I buy Attivare Therapeutics stock?

Attivare Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Attivare Therapeutics's last funding round?

Attivare Therapeutics's most recent funding round was Grant on December 15, 2025.

Who are the main investors in Attivare Therapeutics?

Key investors in Attivare Therapeutics include FundRx.

Will Attivare Therapeutics IPO soon?

No public IPO plans have been announced for Attivare Therapeutics.

How can I track Attivare Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Attivare Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNatick, Massachusetts
Employee Range8
Year Founded2021
Last FundingDec 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?